Skip to content
value.today
Agios Pharmaceuticals Inc. logo

Agios Pharmaceuticals Inc.

Total raised
$87 M
2 rounds on record
Latest round
$78 M
Nov 2011
First round on record
Apr 2010
Today
Went public
See the company page

Agios Pharmaceuticals Inc. is listed today as Agios Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Agios Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2011$78 MNo. 2$50 to $250 million

Agios Pharmaceuticals Inc.: Raise no. 2, Nov 2011

Investors in this round

19 investors had bought by the notice of Nov 22, 2011: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Agios Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$78 M of $78 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Schenkein · Executive Officer, Director
  • Duncan Higgons · Executive Officer
  • Doug Cole · Director
  • John C. Maraganore · Director
  • Kevin C. Starr · Director
  • Lewis C. Cantley · Director
  • Marc C. Tessier-Lavigne · Director
  • Perry C. Karsen · Director
  • Robert Nelsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Schenkein, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 22, 2011. Read the notice at the SEC.

equitySEC
Apr 2010$9 MNo. 1$2 to $10 million

Agios Pharmaceuticals Inc.: Raise no. 1, Apr 2010

Investors in this round

1 investor had bought by the notice of Apr 26, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Agios Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Schenkein · Executive Officer
  • Duncan Higgons · Executive Officer
  • Doug Cole · Director
  • Kevin C. Starr · Director
  • Lewis C. Cantley · Director
  • Robert Nelsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Schenkein, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 26, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Agios Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2011).

    SEC Form D · Nov 2011

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2011

That is all the official record says: Agios Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Agios Pharmaceuticals Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Agios Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Celgene Corp /de/Companynot statednot statedHeld Series B and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Celgene European Investment Co LLCFund or asset managernot statednot statedHeld Series B and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures 2007 General Partner LLCVenture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures Fund 2007, L.P.Venture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series A and C-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding Agios Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Agios Pharmaceuticals Inc.
NameRoleNamed in
David SchenkeinExecutive officerNov 2011
Duncan HiggonsExecutive officerNov 2011
David SchenkeinDirectorNov 2011
Doug ColeDirectorNov 2011
John C. MaraganoreDirectorNov 2011
Kevin C. StarrDirectorNov 2011
Lewis C. CantleyDirectorNov 2011
Marc C. Tessier-LavigneDirectorNov 2011
Perry C. KarsenDirectorNov 2011
Robert NelsenDirectorNov 2011

About

A public American pharmaceutical company.

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.